AbCellera Biologics (ABCL) Income towards Parent Company: 2019-2024
Historic Income towards Parent Company for AbCellera Biologics (ABCL) over the last 6 years, with Dec 2024 value amounting to -$162.9 million.
- AbCellera Biologics' Income towards Parent Company fell 57.73% to -$47.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$146.4 million, marking a year-over-year decrease of 192.35%. This contributed to the annual value of -$162.9 million for FY2024, which is 11.24% down from last year.
- As of FY2024, AbCellera Biologics' Income towards Parent Company stood at -$162.9 million, which was down 11.24% from -$146.4 million recorded in FY2023.
- AbCellera Biologics' Income towards Parent Company's 5-year high stood at $158.5 million during FY2022, with a 5-year trough of -$162.9 million in FY2024.
- Its 3-year average for Income towards Parent Company is -$50.2 million, with a median of -$146.4 million in 2023.
- As far as peak fluctuations go, AbCellera Biologics' Income towards Parent Company spiked by 5,715.65% in 2020, and later slumped by 192.35% in 2023.
- Yearly analysis of 5 years shows AbCellera Biologics' Income towards Parent Company stood at $124.2 million in 2020, then increased by 23.60% to $153.5 million in 2021, then grew by 3.29% to $158.5 million in 2022, then slumped by 192.35% to -$146.4 million in 2023, then fell by 11.24% to -$162.9 million in 2024.